Search results
Results from the WOW.Com Content Network
Deaths. <2% of reported cases. Multisystem inflammatory syndrome in children (MIS-C), or paediatric inflammatory multisystem syndrome (PIMS / PIMS-TS), or systemic inflammatory syndrome in COVID-19 (SISCoV), is a rare systemic illness involving persistent fever and extreme inflammation following exposure to SARS-CoV-2, the virus responsible for ...
The number of COVID-19 infections [4] are highest in subjects between ages 18–65, while the risk of severe disease or death [4] jumps after age 50 and increases with age. About 35% of patients with symptoms of COVID-19 experience neurological complications.
The same is going on with COVID-19 pandemic and while confined in quarantine, according to research, pandemics can have negative effects on children's mental health, but to a lesser extent, both in terms of internal symptoms (e.g., anxiety or depression) and external symptoms (e.g., behavioural disorders, hyperactivity) and the prevalence of ...
The treatment and management of COVID-19 combines both supportive care, which includes treatment to relieve symptoms, fluid therapy, oxygen support as needed, [1][2][3] and a growing list of approved medications. Highly effective vaccines have reduced mortality related to SARS-CoV-2; however, for those awaiting vaccination, as well as for the ...
IC41 is a peptide vaccine candidate against the Hepatitis C virus. It consists of five synthetic peptides along with the synthetic adjuvant called poly-l-arginine. [13] Multimeric-001 is the most efficient peptide vaccine candidate against influenza. It contains B- and T-cell epitopes from Hemagglutinin.
Peptide therapeutics. Peptide therapeutics are peptides or polypeptides (oligomers or short polymers of amino acids) which are used to for the treatment of diseases. Naturally occurring peptides may serve as hormones, growth factors, neurotransmitters, ion channel ligands, and anti-infectives; peptide therapeutics mimic such functions.
COVID-19 drug development is the research process to develop preventative therapeutic prescription drugs that would alleviate the severity of coronavirus disease 2019 (COVID-19). From early 2020 through 2021, several hundred drug companies, biotechnology firms, university research groups, and health organizations were developing therapeutic ...
Substance P (SP) is an undecapeptide (a peptide composed of a chain of 11 amino acid residues) [1] and a type of neuropeptide, belonging to the tachykinin family of neuropeptides. It acts as a neurotransmitter and a neuromodulator. [2][3] Substance P and the closely related neurokinin A (NKA) are produced from a polyprotein precursor after ...